Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review

Date: July 19, 2016
Pages: 67
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A16EE7FD068EN
Leaflet:

Download PDF Leaflet

Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review
Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Alnylam Pharmaceuticals, Inc., (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals, Inc. Key Recent Developments

Jul 12, 2016: Alnylam to Host Third Annual RNAi Roundtable Webcast Series
May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
Apr 28, 2016: Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
Feb 12, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress
Feb 11, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Alnylam Pharmaceuticals, Inc. - Key Facts
    Alnylam Pharmaceuticals, Inc. - Key Employees
    Alnylam Pharmaceuticals, Inc. - Key Employee Biographies
    Alnylam Pharmaceuticals, Inc. - Major Products and Services
    Alnylam Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
    Alnylam Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Alnylam Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Alnylam Pharmaceuticals, Inc. - History
    Alnylam Pharmaceuticals, Inc. - Company Statement
    Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries
    Joint Venture

    SECTION 2 – COMPANY ANALYSIS

    Alnylam Pharmaceuticals, Inc. - Business Description
    Alnylam Pharmaceuticals, Inc. - SWOT Analysis
    SWOT Analysis - Overview
    Alnylam Pharmaceuticals, Inc. - Strengths
    Strength - Liquidity Position
    Strength - Intellectual Property Portfolio
    Strength - Research and Development Activities
    Alnylam Pharmaceuticals, Inc. - Weaknesses
    Weakness - Operating Loss Carryforward
    Alnylam Pharmaceuticals, Inc. - Opportunities
    Opportunity - Strong Product Pipeline
    Opportunity - Orphan Drug Designation
    Opportunity - Market Potential: Diabetes
    Opportunity - Strategic Initiatives
    Alnylam Pharmaceuticals, Inc. - Threats
    Threat - Competitive Environment
    Threat - Stringent Government Regulations
    Threat - Uncertain R&D Outcomes
    Alnylam Pharmaceuticals, Inc. - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Jul 12, 2016: Alnylam to Host Third Annual RNAi Roundtable Webcast Series
    May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
    Feb 12, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress
    Feb 11, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
    Jan 11, 2016: Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline
    Dec 18, 2015: Alnylam Announces Updates to Company’s Board of Directors Supportive of Transition Towards Commercial Stage
    Dec 10, 2015: Alnylam Pharmaceuticals to Present Path to 'Alnylam 2020' at R&D Day
    Nov 09, 2015: Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period
    Oct 29, 2015: Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis
    Oct 28, 2015: BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Alnylam Pharmaceuticals, Inc., Key Facts
    Alnylam Pharmaceuticals, Inc., Key Employees
    Alnylam Pharmaceuticals, Inc., Key Employee Biographies
    Alnylam Pharmaceuticals, Inc., Major Products and Services
    Alnylam Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
    Alnylam Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
    Alnylam Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
    Alnylam Pharmaceuticals, Inc., History
    Alnylam Pharmaceuticals, Inc., Subsidiaries
    Alnylam Pharmaceuticals, Inc., Joint Venture
    Alnylam Pharmaceuticals, Inc., Key Competitors
    Alnylam Pharmaceuticals, Inc., Ratios based on current share price
    Alnylam Pharmaceuticals, Inc., Annual Ratios
    Alnylam Pharmaceuticals, Inc., Interim Ratios
    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Alnylam Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Alnylam Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Alnylam Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
    Alnylam Pharmaceuticals, Inc., Ratio Charts
    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
    Alnylam Pharmaceuticals, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: